Older Age But Not Comorbidity is Associated with Worse Survival in Patients with Hepatocellular Carcinoma

Age and comorbidity are key factors in assessing patient prognosis and informing stopping rules for cancer screening eligibility, but their impact has not been rigorously evaluated in patients with hepatocellular carcinoma (HCC). We conducted a retrospective cohort study of patients diagnosed with H...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical gastroenterology and hepatology 2024-11
Hauptverfasser: Kanneganti, Mounika, Al-Hasan, Mohammed, Bourque, Samantha, Deodhar, Sneha, Yang, Ju Dong, Huang, Daniel Q., Kulkarni, Anand V., Gopal, Purva, Parikh, Neehar D., Kanwal, Fasiha, Patel, Madhukar S., Singal, Amit G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Clinical gastroenterology and hepatology
container_volume
creator Kanneganti, Mounika
Al-Hasan, Mohammed
Bourque, Samantha
Deodhar, Sneha
Yang, Ju Dong
Huang, Daniel Q.
Kulkarni, Anand V.
Gopal, Purva
Parikh, Neehar D.
Kanwal, Fasiha
Patel, Madhukar S.
Singal, Amit G.
description Age and comorbidity are key factors in assessing patient prognosis and informing stopping rules for cancer screening eligibility, but their impact has not been rigorously evaluated in patients with hepatocellular carcinoma (HCC). We conducted a retrospective cohort study of patients diagnosed with HCC at 2 health systems between January 2010 and February 2023. We used multivariable logistic regression and Cox proportional hazards models to evaluate the associations between older age (≥65 years) and comorbidity burden (Charlson Comorbidity Index) with early stage presentation, curative treatment receipt, and overall survival. We performed subgroup analyses in patients with early stage HCC. We identified 2002 patients with HCC (median age, 61 years; 76% male; 21% early stage), with a median survival of 15.7 months. In adjusted analyses, curative treatment receipt was associated with higher comorbidity but not older age. Conversely, overall survival was significantly associated with older age (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.06–1.47) but not high comorbidity (HR, 0.92; 95% CI, 0.77–1.09). Older age continued to be associated with worse survival among patients with early stage HCC (HR, 1.99; 95% CI, 1.45–2.73) and those who underwent curative treatment (HR, 1.52; 95% CI, 1.10–2.10). Median survival for younger versus older individuals was 20 versus 14 months overall, 65 versus 49 months for patients with early stage HCC, and 113 versus 60 months for those with curative treatment. Older age but not comorbidity burden is associated with worse survival in patients with early stage HCC. Further studies are needed to define the role of comorbidity in HCC prognostication.
doi_str_mv 10.1016/j.cgh.2024.10.015
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3131851101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356524010383</els_id><sourcerecordid>3131851101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1507-8c784ff2d32371bd4ef11c17ff148b348d2bf26663a66e1bcc11035b1dbbeb3c3</originalsourceid><addsrcrecordid>eNp9kE9PGzEQxS1UBIH2A3BBPvaS4FnvrjfqKY0oQYoACaoeLf-ZBUe7cWp7g_Lt6ygpR04z43nvafwj5ArYBBjUN6uJeX2bFKwo8zxhUJ2QEVRlMRYCyi_Hnld1dU4uYlwxVkzLqTgj53xaCWiEGBH32FkMdPaK9OeQ6INPdO57H7SzLu2oi3QWozdOJbT03aU3-seHiPR5CFu3VR11a_qkksN1iof9AjcqeYNdN3Qq0LkKxq19r76S01Z1Eb8d6yX5_ev2Zb4YLx_v7uez5dhAxcS4MaIp27awvOACtC2xBTAg2hbKRvOysYVui7quuaprBG0MAOOVBqs1am74Jfl-yN0E_3fAmGTv4v4ctUY_RMmBQ1NlE2QpHKQm-BgDtnITXK_CTgKTe8JyJTNhuSe8f8qEs-f6GD_oHu2H4z_SLPhxEGD-5NZhkNFkPAatC2iStN59Ev8PhzuMYg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3131851101</pqid></control><display><type>article</type><title>Older Age But Not Comorbidity is Associated with Worse Survival in Patients with Hepatocellular Carcinoma</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Kanneganti, Mounika ; Al-Hasan, Mohammed ; Bourque, Samantha ; Deodhar, Sneha ; Yang, Ju Dong ; Huang, Daniel Q. ; Kulkarni, Anand V. ; Gopal, Purva ; Parikh, Neehar D. ; Kanwal, Fasiha ; Patel, Madhukar S. ; Singal, Amit G.</creator><creatorcontrib>Kanneganti, Mounika ; Al-Hasan, Mohammed ; Bourque, Samantha ; Deodhar, Sneha ; Yang, Ju Dong ; Huang, Daniel Q. ; Kulkarni, Anand V. ; Gopal, Purva ; Parikh, Neehar D. ; Kanwal, Fasiha ; Patel, Madhukar S. ; Singal, Amit G.</creatorcontrib><description>Age and comorbidity are key factors in assessing patient prognosis and informing stopping rules for cancer screening eligibility, but their impact has not been rigorously evaluated in patients with hepatocellular carcinoma (HCC). We conducted a retrospective cohort study of patients diagnosed with HCC at 2 health systems between January 2010 and February 2023. We used multivariable logistic regression and Cox proportional hazards models to evaluate the associations between older age (≥65 years) and comorbidity burden (Charlson Comorbidity Index) with early stage presentation, curative treatment receipt, and overall survival. We performed subgroup analyses in patients with early stage HCC. We identified 2002 patients with HCC (median age, 61 years; 76% male; 21% early stage), with a median survival of 15.7 months. In adjusted analyses, curative treatment receipt was associated with higher comorbidity but not older age. Conversely, overall survival was significantly associated with older age (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.06–1.47) but not high comorbidity (HR, 0.92; 95% CI, 0.77–1.09). Older age continued to be associated with worse survival among patients with early stage HCC (HR, 1.99; 95% CI, 1.45–2.73) and those who underwent curative treatment (HR, 1.52; 95% CI, 1.10–2.10). Median survival for younger versus older individuals was 20 versus 14 months overall, 65 versus 49 months for patients with early stage HCC, and 113 versus 60 months for those with curative treatment. Older age but not comorbidity burden is associated with worse survival in patients with early stage HCC. Further studies are needed to define the role of comorbidity in HCC prognostication.</description><identifier>ISSN: 1542-3565</identifier><identifier>ISSN: 1542-7714</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2024.10.015</identifier><identifier>PMID: 39571877</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cirrhosis ; Comorbidity ; Liver Cancer ; Screening ; Surveillance</subject><ispartof>Clinical gastroenterology and hepatology, 2024-11</ispartof><rights>2024</rights><rights>Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-1172-3971</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2024.10.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39571877$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanneganti, Mounika</creatorcontrib><creatorcontrib>Al-Hasan, Mohammed</creatorcontrib><creatorcontrib>Bourque, Samantha</creatorcontrib><creatorcontrib>Deodhar, Sneha</creatorcontrib><creatorcontrib>Yang, Ju Dong</creatorcontrib><creatorcontrib>Huang, Daniel Q.</creatorcontrib><creatorcontrib>Kulkarni, Anand V.</creatorcontrib><creatorcontrib>Gopal, Purva</creatorcontrib><creatorcontrib>Parikh, Neehar D.</creatorcontrib><creatorcontrib>Kanwal, Fasiha</creatorcontrib><creatorcontrib>Patel, Madhukar S.</creatorcontrib><creatorcontrib>Singal, Amit G.</creatorcontrib><title>Older Age But Not Comorbidity is Associated with Worse Survival in Patients with Hepatocellular Carcinoma</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Age and comorbidity are key factors in assessing patient prognosis and informing stopping rules for cancer screening eligibility, but their impact has not been rigorously evaluated in patients with hepatocellular carcinoma (HCC). We conducted a retrospective cohort study of patients diagnosed with HCC at 2 health systems between January 2010 and February 2023. We used multivariable logistic regression and Cox proportional hazards models to evaluate the associations between older age (≥65 years) and comorbidity burden (Charlson Comorbidity Index) with early stage presentation, curative treatment receipt, and overall survival. We performed subgroup analyses in patients with early stage HCC. We identified 2002 patients with HCC (median age, 61 years; 76% male; 21% early stage), with a median survival of 15.7 months. In adjusted analyses, curative treatment receipt was associated with higher comorbidity but not older age. Conversely, overall survival was significantly associated with older age (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.06–1.47) but not high comorbidity (HR, 0.92; 95% CI, 0.77–1.09). Older age continued to be associated with worse survival among patients with early stage HCC (HR, 1.99; 95% CI, 1.45–2.73) and those who underwent curative treatment (HR, 1.52; 95% CI, 1.10–2.10). Median survival for younger versus older individuals was 20 versus 14 months overall, 65 versus 49 months for patients with early stage HCC, and 113 versus 60 months for those with curative treatment. Older age but not comorbidity burden is associated with worse survival in patients with early stage HCC. Further studies are needed to define the role of comorbidity in HCC prognostication.</description><subject>Cirrhosis</subject><subject>Comorbidity</subject><subject>Liver Cancer</subject><subject>Screening</subject><subject>Surveillance</subject><issn>1542-3565</issn><issn>1542-7714</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kE9PGzEQxS1UBIH2A3BBPvaS4FnvrjfqKY0oQYoACaoeLf-ZBUe7cWp7g_Lt6ygpR04z43nvafwj5ArYBBjUN6uJeX2bFKwo8zxhUJ2QEVRlMRYCyi_Hnld1dU4uYlwxVkzLqTgj53xaCWiEGBH32FkMdPaK9OeQ6INPdO57H7SzLu2oi3QWozdOJbT03aU3-seHiPR5CFu3VR11a_qkksN1iof9AjcqeYNdN3Qq0LkKxq19r76S01Z1Eb8d6yX5_ev2Zb4YLx_v7uez5dhAxcS4MaIp27awvOACtC2xBTAg2hbKRvOysYVui7quuaprBG0MAOOVBqs1am74Jfl-yN0E_3fAmGTv4v4ctUY_RMmBQ1NlE2QpHKQm-BgDtnITXK_CTgKTe8JyJTNhuSe8f8qEs-f6GD_oHu2H4z_SLPhxEGD-5NZhkNFkPAatC2iStN59Ev8PhzuMYg</recordid><startdate>20241120</startdate><enddate>20241120</enddate><creator>Kanneganti, Mounika</creator><creator>Al-Hasan, Mohammed</creator><creator>Bourque, Samantha</creator><creator>Deodhar, Sneha</creator><creator>Yang, Ju Dong</creator><creator>Huang, Daniel Q.</creator><creator>Kulkarni, Anand V.</creator><creator>Gopal, Purva</creator><creator>Parikh, Neehar D.</creator><creator>Kanwal, Fasiha</creator><creator>Patel, Madhukar S.</creator><creator>Singal, Amit G.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1172-3971</orcidid></search><sort><creationdate>20241120</creationdate><title>Older Age But Not Comorbidity is Associated with Worse Survival in Patients with Hepatocellular Carcinoma</title><author>Kanneganti, Mounika ; Al-Hasan, Mohammed ; Bourque, Samantha ; Deodhar, Sneha ; Yang, Ju Dong ; Huang, Daniel Q. ; Kulkarni, Anand V. ; Gopal, Purva ; Parikh, Neehar D. ; Kanwal, Fasiha ; Patel, Madhukar S. ; Singal, Amit G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1507-8c784ff2d32371bd4ef11c17ff148b348d2bf26663a66e1bcc11035b1dbbeb3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cirrhosis</topic><topic>Comorbidity</topic><topic>Liver Cancer</topic><topic>Screening</topic><topic>Surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanneganti, Mounika</creatorcontrib><creatorcontrib>Al-Hasan, Mohammed</creatorcontrib><creatorcontrib>Bourque, Samantha</creatorcontrib><creatorcontrib>Deodhar, Sneha</creatorcontrib><creatorcontrib>Yang, Ju Dong</creatorcontrib><creatorcontrib>Huang, Daniel Q.</creatorcontrib><creatorcontrib>Kulkarni, Anand V.</creatorcontrib><creatorcontrib>Gopal, Purva</creatorcontrib><creatorcontrib>Parikh, Neehar D.</creatorcontrib><creatorcontrib>Kanwal, Fasiha</creatorcontrib><creatorcontrib>Patel, Madhukar S.</creatorcontrib><creatorcontrib>Singal, Amit G.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanneganti, Mounika</au><au>Al-Hasan, Mohammed</au><au>Bourque, Samantha</au><au>Deodhar, Sneha</au><au>Yang, Ju Dong</au><au>Huang, Daniel Q.</au><au>Kulkarni, Anand V.</au><au>Gopal, Purva</au><au>Parikh, Neehar D.</au><au>Kanwal, Fasiha</au><au>Patel, Madhukar S.</au><au>Singal, Amit G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Older Age But Not Comorbidity is Associated with Worse Survival in Patients with Hepatocellular Carcinoma</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2024-11-20</date><risdate>2024</risdate><issn>1542-3565</issn><issn>1542-7714</issn><eissn>1542-7714</eissn><abstract>Age and comorbidity are key factors in assessing patient prognosis and informing stopping rules for cancer screening eligibility, but their impact has not been rigorously evaluated in patients with hepatocellular carcinoma (HCC). We conducted a retrospective cohort study of patients diagnosed with HCC at 2 health systems between January 2010 and February 2023. We used multivariable logistic regression and Cox proportional hazards models to evaluate the associations between older age (≥65 years) and comorbidity burden (Charlson Comorbidity Index) with early stage presentation, curative treatment receipt, and overall survival. We performed subgroup analyses in patients with early stage HCC. We identified 2002 patients with HCC (median age, 61 years; 76% male; 21% early stage), with a median survival of 15.7 months. In adjusted analyses, curative treatment receipt was associated with higher comorbidity but not older age. Conversely, overall survival was significantly associated with older age (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.06–1.47) but not high comorbidity (HR, 0.92; 95% CI, 0.77–1.09). Older age continued to be associated with worse survival among patients with early stage HCC (HR, 1.99; 95% CI, 1.45–2.73) and those who underwent curative treatment (HR, 1.52; 95% CI, 1.10–2.10). Median survival for younger versus older individuals was 20 versus 14 months overall, 65 versus 49 months for patients with early stage HCC, and 113 versus 60 months for those with curative treatment. Older age but not comorbidity burden is associated with worse survival in patients with early stage HCC. Further studies are needed to define the role of comorbidity in HCC prognostication.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39571877</pmid><doi>10.1016/j.cgh.2024.10.015</doi><orcidid>https://orcid.org/0000-0002-1172-3971</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1542-3565
ispartof Clinical gastroenterology and hepatology, 2024-11
issn 1542-3565
1542-7714
1542-7714
language eng
recordid cdi_proquest_miscellaneous_3131851101
source Elsevier ScienceDirect Journals Complete
subjects Cirrhosis
Comorbidity
Liver Cancer
Screening
Surveillance
title Older Age But Not Comorbidity is Associated with Worse Survival in Patients with Hepatocellular Carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A23%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Older%20Age%20But%20Not%20Comorbidity%20is%20Associated%20with%20Worse%20Survival%20in%20Patients%20with%20Hepatocellular%20Carcinoma&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Kanneganti,%20Mounika&rft.date=2024-11-20&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2024.10.015&rft_dat=%3Cproquest_cross%3E3131851101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3131851101&rft_id=info:pmid/39571877&rft_els_id=S1542356524010383&rfr_iscdi=true